Some hepatologists also use a positive result to urge insurance companies to pay for more frequent and intensive imaging. Ultimately AFP-L3% may be used as a rule-in or rule-out assay for transplantation consideration and/or an intermediate step in surveillance precluding costly imaging on patients with fluctuating AFP results but negative for HCC.